SLP News and Press, Simulations Plus Inc. From 03/21/23

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wedn...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtuall...

Promising intellectual property resulting from the collaboration with Polish Academy of Sciences will be jointly owned for further development opportunities Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical...

Update includes enhanced PKanalix, Monolix, and Simulx modules Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading provider of popu...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 33 rd Annual Healthcare Conference taking place virtually from March 13-...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates’ 44 th Annual Institutional Investors Conference, s...

Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical...

NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure Simulations Plus, Inc . (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFL...

Summary Simulations Plus has been beaten down over the FY22' period to date, but has curled up off lows into the new year. It is a niche operator presenting with a differentiated offering for those speculating on clinical-stage assets. Shares are richly priced but this can be justif...

DSX is faster, more user-friendly, and scalable for high-performance computing Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) div...